2019 San Antonio Breast Cancer Symposium Coverage
Every December, the San Antonio Breast Cancer Symposium brings together clinicians, researchers, and advocates to discuss the latest breast cancer study results. We’re proud to present our coverage below.
Research news
FDA Approves Enhertu for Unresectable or Pretreated Metastatic HER2-Positive Breast Cancer
Is Oral Paclitaxel Better Than IV Paclitaxel for Metastatic Breast Cancer?
Podcast episodes
SABCS 2019: Five More Years of Femara Seems to Reduce Breast Cancer Recurrence Risk for Some Women, with Terry Mamounas, MD, MPH, FACS
SABCS 2019: MRI Finds Breast Cancers Earlier Than Mammography in Women With Strong Family History, with Madeleine Tilanus-Linthorst, PhD
SABCS 2019: Arimidex for Breast Cancer Prevention: Benefits Last Nearly 6 Years After Treatment Ends, with Jack Cuzick, PhD
SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?, with Rashmi Murthy, MD
Top News at 2019 SABCS – Heard in the Halls: Voices From the 2019 SABCS, with Jack Goodpasture
Does Immunotherapy Before Breast Cancer Surgery Offer Benefits – Heard in the Halls: Voices From the 2019 SABCS, with Luca Gianni, MD
GRASP: Empowering Patients With Knowledge – Heard in the Halls: Voices From the 2019 SABCS, with Felicia Johnson and Sharon Rivera-Sanchez
Why Sexual Health Is Crucial for People With Metastatic Breast Cancer – Heard in the Halls: Voices From the 2019 SABCS, with Stephanie Graff, MD
Mets, Sex, and Side Effects – Heard in the Halls: Voices From the 2019 SABCS, with Kelly Shanahan, MD
Beneath the Breast – Heard in the Halls: Voices From the 2019 SABCS, with Barbara Bigelow
— Last updated on January 8, 2022, 7:57 PM